Long-term safety and effectiveness of stiripentol in patients with Dravet syndrome: Interim report of a post-marketing surveillance study in Japan
| Autor: | Daisuke Matsui, Katsuyoshi Suzuki, Yushi Inoue, Miyuki Yamada, Yoko Ohtsuka |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Generalized myoclonic seizures Adult Pediatrics medicine.medical_specialty Clobazam Adolescent Postmarketing surveillance Epilepsies Myoclonic 03 medical and health sciences Epilepsy Young Adult 0302 clinical medicine Dravet syndrome Japan Seizures Stiripentol Product Surveillance Postmarketing Medicine Humans Prospective cohort study Child business.industry Infant Dioxolanes Middle Aged medicine.disease 030104 developmental biology Neurology Pharmaceutical Preparations Child Preschool Anticonvulsants Neurology (clinical) business Epileptic Syndromes Spasms Infantile 030217 neurology & neurosurgery Adverse drug reaction medicine.drug |
| Zdroj: | Epilepsy research. 170 |
| ISSN: | 1872-6844 |
| Popis: | Background A post-marketing surveillance study is investigating the safety and effectiveness of stiripentol during real-world clinical use in Japanese patients with Dravet syndrome (DS). Methods The safety and effectiveness of stiripentol were prospectively investigated over 104 weeks in all patients with DS who were administered the drug from November 2012 through July 2019 in Japan. Patients administered stiripentol for the first time after its approval were defined as “new patients,” and those who continued to take the drug after participating in domestic clinical studies were defined as “continuous-use patients.” The responder rate was defined as the proportion of patients with a ≥50 % decrease in seizure episodes at the time of assessment of stiripentol effectiveness compared with the 4 weeks before starting stiripentol. Overall improvement was evaluated by the physician in charge based on the comprehensive assessment of the patient’s condition after stiripentol treatment. Results Of 411 patients whose information was collected, 410 patients (376 new and 34 continuous-use) were included in the safety analysis set, and 409 (376 new and 33 continuous-use) were included in the effectiveness analysis set. The median age of new patients was 7 years (range: 0.5–50 years) at the time of stiripentol initiation; 99 % of patients were taking concomitant sodium valproate and 93 % clobazam. Adverse drug reactions occurred in 70 % of new patients; the most common were somnolence (39 %) and loss of appetite (25 %). No new safety concerns due to stiripentol were observed. The responder rate in new patients was 43 % (110/257 patients) for convulsive seizures (tonic-clonic and/or clonic convulsions), 55 % (58/105 patients) for focal impaired awareness seizures, and 62 % (56/90 patients) for generalized myoclonic seizures and/or generalized atypical absence seizures. Overall improvement (after 104 weeks or at the time of drug discontinuation) was rated as marked or moderate in 160/353 of new patients (45 %). Conclusion Stiripentol is safe and effective during long-term use in patients with DS in routine clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect